Fig. 1: Administration of targeted treatment regimens in patients with KRAS wildtype mPDAC. | Nature Communications

Fig. 1: Administration of targeted treatment regimens in patients with KRAS wildtype mPDAC.

From: Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma

Fig. 1

a Swimmer’s plot showing the duration of each treatment regimen received by each patient with KRAS wildtype mPDAC (n = 9). Best response to first-line therapy is indicated by black symbols. Black arrows at the end of bars indicate patients who remain on treatment. b Kaplan–Meier curve comparing overall survival between KRAS wildtype (n = 9) and mutant (n = 51) groups. Hazard ratio (HR), 95% confidence interval (CI), and log-rank p value are shown. c Forest plot showing results of multivariate survival analysis (n = 60). Significance of KRAS wildtype status (p value) shown is based on the Wald statistic. For each covariate, dots represent the hazard ratio and lines represent 95% confidence intervals. Source data are provided as a Source Data file.

Back to article page